Home Companies Angitia Biopharmaceuticals COMPANY
Clinical Phase 3
7 open jobs · last seen Oct 23, 2026 · 10 sources
Location: Westlake Village, CA · source · Oct 12, 2026
Profile checked Oct 10, 2026
Keywords: Degenerative Disc Disease Pharmacokinetic Study Osteogenesis Imperfecta Postmenopausal Osteoporosis Osteoporosis AGA2118 AGA2115 AGA111 Show all 8 keywords
Since the raise (Feb 5, 2026): 7 of 7 open jobs were first seen after it.
Hiring Title Location (from posting) Employer posted First seen Sr. Manager/Associate Director, Regulatory Writer Remote Oct 20, 2026 Oct 21, 2026 Director, Global Regulatory Affairs Remote Oct 5, 2026 Oct 9, 2026 Scientist to Sr. Scientist, Pharmacology Guangzhou, China Sep 8, 2026 Oct 9, 2026 Research Assistant to Associate Scientist, Pharmacology Guangzhou, China Sep 7, 2026 Oct 9, 2026 Sr. Accountant Guangzhou, China Aug 4, 2026 Oct 9, 2026
See all 7 jobs
At a glance HQ Westlake Village, CA source Stage Clinical Phase 3 Latest trial Phase 1: An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) (Jan 5, 2026) source Timeline Oct 9, 2026 Board tracked Radar started tracking this company’s job board (7 open jobs at last check). source ↗ Feb 5, 2026 Raise Private equity round — Series D: $130M (total, as published), announced Feb 5, 2026. Source: company release on GlobeNewswire. source ↗ Jan 5, 2026 Trial start Phase 1: An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) source ↗ Dec 12, 2025 Trial start Phase 2: Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) source ↗ Dec 11, 2024 Raise Private equity round — Series C: $120M (total, as published), announced Dec 11, 2024. Source: company release on GlobeNewswire. source ↗ Oct 31, 2024 Trial start Phase 2: A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) source ↗ Dec 8, 2023 Trial start 3: A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion source ↗ Oct 3, 2023 Trial start Phase 1: A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers source ↗ Jun 28, 2022 Trial start Phase 1: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women source ↗ Dec 1, 2020 Trial start I: A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease source ↗ Upcoming milestones 2026-12 (ESTIMATED) · Phase 2 · A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) · NCT06577935 2027-11 (ESTIMATED) · Phase 2 · Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) · NCT07062588 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 7 Title Location (from posting, not HQ) Employer posted First seen Level Sr. Manager/Associate Director, Regulatory Writer Remote Oct 20, 2026 Oct 21, 2026 Not stated Director, Global Regulatory Affairs Remote Oct 5, 2026 Oct 9, 2026 Senior Description Scientist to Sr. Scientist, Pharmacology Guangzhou, China Sep 8, 2026 Oct 9, 2026 Senior Description Research Assistant to Associate Scientist, Pharmacology Guangzhou, China Sep 7, 2026 Oct 9, 2026 Mid Description Sr. Accountant Guangzhou, China Aug 4, 2026 Oct 9, 2026 Senior Description Medical Director / Senior Medical Director Remote Jul 23, 2026 Oct 9, 2026 Senior Description Scientist to Sr. Scientist, Discovery Research Guangzhou, China May 18, 2026 Oct 9, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Funding Raised: $250.0M. Last 2 years.
Feb 5, 2026 Private equity round — Series D: $130M (total, as published), announced Feb 5, 2026. Source: company release on GlobeNewswire. source ↗ Dec 11, 2024 Private equity round — Series C: $120M (total, as published), announced Dec 11, 2024. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 7 Record Title Phase Status Start Primary completion NCT07361354 An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS) Phase 1 Completed Jan 5, 2026 Sep 5, 2026 (actual) NCT07062588 Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) Phase 2 Recruiting Dec 12, 2025 2027-11 (estimated) NCT06115512 A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion 3 Terminated Dec 8, 2023 Nov 28, 2025 (actual) NCT06577935 A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) Phase 2 Active, not recruiting Oct 31, 2024 2026-12 (estimated) NCT06086613 A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers Phase 1 Completed Oct 3, 2023 Oct 17, 2024 (actual) NCT05225857 A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women Phase 1 Completed Jun 28, 2022 Jan 13, 2024 (actual) NCT05574543 A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease I Completed Dec 1, 2020 Jul 13, 2022 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗ Investor Listed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗ 